Sangamo Therapeutics Inc. (OTCQB: SGMO) announced it has retained Raymond James as financial advisor to evaluate strategic alternatives aimed at advancing its drug pipeline and maximizing stakeholder value.

The genomic medicine company cited extensive consideration of its pipeline and financial resources as factors behind the decision. Chief Executive Officer Sandy Macrae said the company seeks to continue advancing its assets to patients through this strategic review process.

Sangamo's primary asset is isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease that has completed its registrational Phase 1/2 STAAR study with 32 patients. The treatment has received multiple regulatory designations including Orphan Drug, Fast Track, and RMAT designations from the FDA. The company has initiated a rolling submission of its Biologics License Application to the FDA under the Accelerated Approval pathway.

The company's pipeline includes ST-503 for chronic neuropathic pain, currently in Phase 1/2 trials with seven activated sites, and ST-506 for prion disease, which is in clinical trial application enabling activities. Both programs have received FDA Fast Track designation.

Sangamo's technology platforms include its proprietary STAC-BBB capsid for central nervous system delivery, which has been licensed to Genentech, Astellas and Eli Lilly. The company has received $88 million in license fees to date with potential future milestones and exercise fees of up to $4.6 billion.

The company maintains a patent estate covering 834 patents and patent applications across 90 patent families. No timeline has been established for completing the strategic evaluation process, and no transaction agreements have been reached.

Interested parties may contact the company at [email protected] according to the announcement.